Non-selective potent dopamine reuptake inhibitor

Potent competitive inhibitor of indoleamine 2,3-dioxygenase (IDO)

Potent ß-amyloid aggregation inhibitor; Antioxidant

Novel antiestrogen, lacking estrogenic and genotoxic actions

Novel potent inhibitor of Staphylococcus aureus sortase A (SrtA)

Novel selective CXCR2 antagonist

Novel potent SIRT1 activator

Novel Sirtuin1 Activator, Down-Regulating Sclerostin and Rescuing Ovariectomy-Induced Bone Loss

Novel MOR agonist/DOR antagonist that produced systemically active potent antinociceptive activity in tail-flick assay in mice

Novel GLUT inhibitor, preferentially inhibiting the growth of GBM cells with minimal toxicity to non-neoplastic astrocytes and neurons, also inhibiting glucose uptake and decrease the glycolytic capacity and glycolytic reserve capacity of GBM patient-deri

Novel GLUT inhibitor, preferentially inhibiting the growth of GBM cells with minimal toxicity to non-neoplastic astrocytes and neurons, also inhibiting glucose uptake and decrease the glycolytic capacity and glycolytic reserve capacity of GBM patient-deri

Novel potent inhibitor of Wn/ß-catenin signaling in cancer cells

Novel inhibitor of thrombospondin 1 activation of TGF-β, blocking TGF-β activation (pIC50 = 8.12 nM) and has a plasma half life of 1.8 h (iv)

Potent DAT allosteric modulator, partially inhibiting DAT uptake without altering DAT-mediated reverse transport and with minimal inhibition of DAT binding

Highly blood-brain barrier permeant, potent, and selective for LRRK2 kinase activity, being effective in attenuating pro-inflammatory responses in macrophages and rescuing neurite retraction phenotypes in neurons.

Novel mixed μ opioid receptor (MOR) agonist and δ/κ opioid receptor (DOR/KOR) antagonist

Novel inhibitor of sterol regulatory element-binding protein (SREBP), impairing the SREBP activity by inhibiting glucose transporters and thereby activating AMP-activated protein kinase (AMPK)

Peptide substrate for many protein kinases, such as Blk, BTK, cKit, EPHA1, EPHB2, EPHB3, ERBB4, FAK, Flt3, IGF-1R, ITK, Lck, MET, MUSK, Ret, Src, TIE2, TrkB, VEGF-R1 (Flt-1) and VEGF-R2 (KDR)

Novel Selective TBK1/IKK dual inhibitor with anticancer potency

The first selective β3 adrenergic agonist, showing to possess a profile of antidepressant activity in rodents

Novel renin inhibitor

Novel Inhibitor of c-Jun N-terminal Kinase 3 (JNK3)

Potent inhibitor of both JNK3 and p38

Novel NR4A nuclear receptor modulator

Novel partial agonist of PPARgamma

Novel Unc-51-Like Kinase 1 (ULK1)

Selective neurotensin antagonist

Novel NR4A nuclear receptor modulator

Novel NR4A nuclear receptor modulator

Novel inhibitor of the in vivo aggregation of